1
|
Borghol AH, Alkhatib B, Zayat R, Ravikumar NPG, Munairdjy Debeh FG, Ghanem A, Mina J, Mao MA, Dahl NK, Hickson LJ, Aslam N, Torres VE, Brown RD, Tawk RG, Chebib FT. Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Practical Approach to Screening and Management. Mayo Clin Proc 2025:S0025-6196(25)00080-1. [PMID: 40319406 DOI: 10.1016/j.mayocp.2025.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2024] [Revised: 01/22/2025] [Accepted: 02/07/2025] [Indexed: 05/07/2025]
Abstract
Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent genetic kidney disorder, is characterized by diffuse kidney cysts, hypertension, and progressive kidney function decline, often leading to kidney failure by the age of 60 years. Compared with the general population, patients with ADPKD have an increased risk for development of saccular intracranial aneurysms (IAs), which can lead to intracranial bleeding and result in significant disability and mortality. Of both modifiable and nonmodifiable risk factors, the most significant is a family history of IAs or aneurysm rupture. Other contributing factors include hypertension, cigarette smoking, age, and sex. Most IAs currently detected during screening tests are small and located in the anterior circulation. Intracranial aneurysms can be manifested with thunderclap headache, which may be indicative of subarachnoid hemorrhage. Less commonly, IAs cause symptoms related to mass effect with focal neurologic deficits. Subarachnoid hemorrhage is particularly concerning, given its high case-fatality rate, which remains around 35% despite advances in neurologic care. Therefore, control of risk factors, early detection, and treatment when indicated are important to prevent adverse outcomes. Screening for IAs in ADPKD remains controversial and can be approached either universally (screening of all ADPKD patients) or selectively (screening of high-risk patients). The preferred imaging modality is brain magnetic resonance angiography without contrast enhancement or alternatively computed tomography angiography. This review provides a practical guide for medical teams managing patients with ADPKD, detailing the characteristics of IAs and their associated symptoms. It presents an algorithm for risk assessment and screening along with recommendations for treatment and follow-up care.
Collapse
Affiliation(s)
- Abdul Hamid Borghol
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL; Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL
| | - Bassel Alkhatib
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL; Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL
| | - Roaa Zayat
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL; Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL
| | | | - Fadi George Munairdjy Debeh
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL; Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL
| | - Ahmad Ghanem
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL; Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL
| | - Jonathan Mina
- Department of Internal Medicine, Staten Island University Hospital, Northwell Health, NY
| | - Michael A Mao
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL
| | - Neera K Dahl
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN
| | - LaTonya J Hickson
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL
| | - Nabeel Aslam
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL
| | - Vicente E Torres
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN
| | - Robert D Brown
- Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN
| | - Rabih G Tawk
- Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL
| | - Fouad T Chebib
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL; Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL.
| |
Collapse
|
2
|
Cadnapaphornchai MA, Dell KM, Gimpel C, Guay-Woodford LM, Gulati A, Hartung EA, Liebau MC, Mallett AJ, Marlais M, Mekahli D, Piccirilli A, Seeman T, Tindal K, Winyard PJD. Polycystic Kidney Disease in Children: The Current Status and the Next Horizon. Am J Kidney Dis 2025:S0272-6386(25)00772-3. [PMID: 40113156 DOI: 10.1053/j.ajkd.2025.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2024] [Revised: 01/17/2025] [Accepted: 01/24/2025] [Indexed: 03/22/2025]
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are inherited disorders that share many features such as kidney cysts, hypertension, urinary concentrating defects, and progressive chronic kidney disease. Underlying pathogenic mechanisms for both include cilia dysfunction and dysregulated intracellular signaling. ADPKD has been traditionally regarded as an adult-onset disease, whereas ARPKD has been classically described as an infantile or childhood condition. However, clinicians must recognize that both disorders can present across all age groups ranging from fetal life and infancy to childhood and adolescence, as well as adulthood. Here we highlight the points of overlap and distinct features for these disorders with respect to pathogenesis, diagnostic modalities (radiological and genetic), clinical assessment, and early therapeutic management. In particular, we consider key issues at two critical points for transition of care, i.e., fetal life to infancy and adolescence to adulthood. These timepoints are poorly covered in the extant literature. Therefore, we recommend guiding principles for transitions of clinical care at these critical junctures in the lifespan. While there is no cure for polycystic kidney disease (PKD), recent insights into pathogenic mechanisms have identified promising therapeutic targets that are currently being evaluated in a growing portfolio of clinical trials. We summarize the key findings from these largely adult-based trials and discuss the implications for designing child-focused studies. Finally, we look forward to the next horizon for childhood PKD, highlighting gaps in our current knowledge, and discussing future directions and strategies to attenuate the full burden of disease for children affected with PKD.
Collapse
Affiliation(s)
| | - Katherine M Dell
- Cleveland Clinic Children's Institute and Case Western Reserve University, Cleveland, USA
| | | | - Lisa M Guay-Woodford
- Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, USA.
| | - Ashima Gulati
- Children's National Hospital and the George Washington University, Washington, DC, USA
| | - Erum A Hartung
- Children's Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, USA
| | - Max C Liebau
- University Hospital Cologne and the University of Cologne, Cologne, Germany
| | - Andrew J Mallett
- Townsville University Hospital and James Cook University , Queensland, Australia
| | - Matko Marlais
- Great Ormond Street Hospital for Children and UCL Great Ormond Street Institute of Child Health, London, UK
| | - Djalila Mekahli
- KU Leuven University and UZ Leuven Hospital, Leuven, Belgium
| | | | - Tomas Seeman
- Charles University and Ostrava University, Prague and Ostrava, Czech Republic
| | | | | |
Collapse
|
3
|
Bracciamà V, Vaisitti T, Mioli F, Faini AC, Del Prever GMB, Martins VH, Camilla R, Mattozzi F, Pieretti S, Luca M, Romeo CM, Saglia C, Migliorero M, Arruga F, Carli D, Amoroso A, Lonardi P, Deaglio S, Peruzzi L. Matching clinical and genetic data in pediatric patients at risk of developing cystic kidney disease. Pediatr Nephrol 2025; 40:743-753. [PMID: 39384646 PMCID: PMC11747002 DOI: 10.1007/s00467-024-06548-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2024] [Revised: 09/11/2024] [Accepted: 09/27/2024] [Indexed: 10/11/2024]
Abstract
BACKGROUND Cystic kidney disease is a heterogeneous group of hereditary and non-hereditary pathologic conditions, associated with the development of renal cysts. These conditions may be present both in children and adults. Cysts can even be observed already during the prenatal age, and pediatric patients with cysts need to be clinically monitored. An early clinical and genetic diagnosis is therefore mandatory for optimal patient management. The aim of this study was to perform genetic analyses in patients with echographic evidence of kidney cysts to provide an early molecular diagnosis. METHODS A cohort of 70 pediatric patients was enrolled and clinically studied at the time of first recruitment and at follow-up. Genetic testing by clinical exome sequencing was performed and a panel of genes responsible for "cystic kidneys" was analyzed to identify causative variants. Sanger validation and segregation studies were exploited for the final classification of the variants and accurate genetic counseling. RESULTS Data showed that 53/70 of pediatric patients referred with a clinical suspicion of cystic kidney disease presented a causative genetic variant. In a significant proportion of the cohort (24/70), evidence of hyper-echogenic/cystic kidneys was already present in the prenatal period, even in the absence of a positive family history. CONCLUSIONS This study suggests that cystic kidney disease may develop since the very early stages of life and that screening programs based on ultrasound scans and genetic testing play a critical role in diagnosis, allowing for better clinical management and tailored genetic counseling to the family.
Collapse
Affiliation(s)
- Valeria Bracciamà
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Tiziana Vaisitti
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy.
| | - Fiorenza Mioli
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Angelo Corso Faini
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Giulia Margherita Brach Del Prever
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Vitor Hugo Martins
- Nephrology Dialysis and Transplantation, ERKNet Center, Regina Margherita Children's Hospital, Turin, Italy
| | - Roberta Camilla
- Nephrology Dialysis and Transplantation, ERKNet Center, Regina Margherita Children's Hospital, Turin, Italy
| | - Francesca Mattozzi
- Nephrology Dialysis and Transplantation, ERKNet Center, Regina Margherita Children's Hospital, Turin, Italy
| | - Silvia Pieretti
- Nephrology Dialysis and Transplantation, ERKNet Center, Regina Margherita Children's Hospital, Turin, Italy
| | - Maria Luca
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Carmelo Maria Romeo
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Claudia Saglia
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Martina Migliorero
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Francesca Arruga
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Diana Carli
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Antonio Amoroso
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Pietro Lonardi
- Nephrology Dialysis and Transplantation, ERKNet Center, Regina Margherita Children's Hospital, Turin, Italy
| | - Silvia Deaglio
- Immunogenetics and Transplant Biology, AOU Città della Salute e della Scienza, ERKNet Center & Department of Medical Sciences, University of Turin, Turin, Italy
| | - Licia Peruzzi
- Nephrology Dialysis and Transplantation, ERKNet Center, Regina Margherita Children's Hospital, Turin, Italy
| |
Collapse
|
4
|
Devuyst O, Ahn C, Barten TR, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JP, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong AC, Onuchic LF, P-C Pei Y, Perrone RD, Rangan GK, Rayner B, Torra R, Mustafa R, Torres VE. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025; 107:S1-S239. [PMID: 39848759 DOI: 10.1016/j.kint.2024.07.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2024] [Accepted: 07/17/2024] [Indexed: 01/25/2025]
|
5
|
Trutin I, Oletić L, Nikuševa-Martić T. Unraveling the Complexity of Childhood Polycystic Kidney Disease: A Case Study of Three Sisters. CHILDREN (BASEL, SWITZERLAND) 2023; 10:1700. [PMID: 37892363 PMCID: PMC10605507 DOI: 10.3390/children10101700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 10/11/2023] [Accepted: 10/15/2023] [Indexed: 10/29/2023]
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder, estimated to affect 1 in 1000 people. It displays a high level of variability in terms of onset and severity among affected individuals within the same family. In this case study, three sisters (4, 8, and 10 years of age) were suspected of having ADPKD due to their positive family history. While the two younger sisters aged 8 and 4 showed no disease complications and had normal kidney function, the oldest sister was found to have no dipping status on ambulatory blood pressure measurement (ABPM). Two of the sisters were discovered to have a PKD1 mutation, while the third sister aged 8 was heterozygous for TTC21B c.1593_1595del, p. (Leu532del), which is a variant of uncertain significance (VUS). Environmental factors and genetic modifying factors are believed to contribute to the phenotypic variability observed in ADPKD. Identifying and understanding potential genetic and environmental modifiers of ADPKD could pave the way to targeted treatments for childhood ADPKD.
Collapse
Affiliation(s)
- Ivana Trutin
- Department of Pediatrics, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia; (I.T.); (L.O.)
| | - Lea Oletić
- Department of Pediatrics, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia; (I.T.); (L.O.)
| | | |
Collapse
|
6
|
Martínez V, Furlano M, Sans L, Pulido L, García R, Pérez-Gómez MV, Sánchez-Rodríguez J, Blasco M, Castro-Alonso C, Fernández-Fresnedo G, Robles NR, Valenzuela MP, Naranjo J, Martín N, Pilco M, Agraz-Pamplona I, González-Rodríguez JD, Panizo N, Fraga G, Fernández L, López MT, Dall'Anese C, Ortiz A, Torra R. Autosomal dominant polycystic kidney disease in young adults. Clin Kidney J 2023; 16:985-995. [PMID: 37260991 PMCID: PMC10229292 DOI: 10.1093/ckj/sfac251] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Indexed: 02/07/2025] Open
Abstract
BACKGROUND The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze the clinical characteristics of ADPKD in young adults. METHODS Family history, hypertension, albuminuria, estimated glomerular filtration rate (eGFR) and imaging tests were examined in 346 young adults (18-30 years old) out of 2521 patients in the Spanish ADPKD registry (REPQRAD). A literature review searched for reports on hypertension in series with more than 50 young (age <30 years) ADPKD patients. RESULTS The mean age of this young adult cohort was 25.24 (SD 3.72) years. The mean age at diagnosis of hypertension was 21.15 (SD 4.62) years, while in the overall REPQRAD population was aged 37.6 years. The prevalence of hypertension was 28.03% and increased with age (18-24 years, 16.8%; 25-30 years, 36.8%). Although prevalence was lower in women than in men, the age at onset of hypertension (21 years) was similar in both sexes. Mean eGFR was 108 (SD 21) mL/min/1.73 m2, 38.0% had liver cysts and 3.45% of those studied had intracranial aneurysms. In multivariate analyses, hematuria episodes and kidney length were independent predictors of hypertension (area under the curve 0.75). The prevalence of hypertension in 22 pediatric cohorts was 20%-40%, but no literature reports on hypertension in young ADPKD adults were found. CONCLUSIONS Young adults present non-negligible ADPKD-related morbidity. This supports the need for a thorough assessment of young adults at risk of ADPKD that allows early diagnosis and treatment of hypertension.
Collapse
Affiliation(s)
- Víctor Martínez
- Nephrology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
| | - Mónica Furlano
- Inherited Kidney Diseases, Nephrology Department, Fundació Puigvert, Institut d'Investigació Biomèdica Sant Pau (IIB-SANT PAU)
| | - Laia Sans
- Nephrology Department, Hospital del Mar, Barcelona, Spain
| | - Lissett Pulido
- Nephrology Department, Hospital Universitario Joan XXIII, Tarragona, Spain
| | - Rebeca García
- Nephrology Department, Hospital La Mancha-Centro, Alcázar de San Juan, Spain
| | - María Vanessa Pérez-Gómez
- Nephrology Department, IIS-Fundación Jiménez Diaz, Universidad Autónoma de Madrid, IRSIN, RICORS40, Madrid, Spain
| | - Jinny Sánchez-Rodríguez
- Nephrology Department, IIS-Fundación Jiménez Diaz, Universidad Autónoma de Madrid, IRSIN, RICORS40, Madrid, Spain
| | - Miquel Blasco
- Nephrology and Kidney Transplantation Department, Hospital Clínic, Institute of Biomedical Research August Pi i Sunyer (IDIPABS), University of Barcelona, Barcelona, Spain
| | | | | | | | | | - Javier Naranjo
- Nephrology Department, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - Nadia Martín
- Nephrology Department, Hospital Universitari de Girona Dr Josep Trueta, Gerona, Spain
| | - Melissa Pilco
- Nephrology Department, Hospital Universitari de Girona Dr Josep Trueta, Gerona, Spain
| | | | | | - Nayara Panizo
- Nephrology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - Gloria Fraga
- Pediatric Nephrology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - Loreto Fernández
- Nephrology Department, Hospital Príncipe de Asturias, Alcalá de Henares, Spain
| | | | | | - Alberto Ortiz
- Nephrology Department, IIS-Fundación Jiménez Diaz, Universidad Autónoma de Madrid, IRSIN, RICORS40, Madrid, Spain
| | - Roser Torra
- Inherited Kidney Diseases, Nephrology Department, Fundació Puigvert, Institut d’Investigació Biomèdica Sant Pau (IIB-SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|